Europian Perspectives Archive

Depressive Symptom Profiles and Survival in Older Patients with Cancer: Latent Class Analysis of the ELCAPA Cohort Study

Clément Gouraud, Elena Paillaud, Claudia Martinez-Tapia, Lauriane Segaux, Nicoleta Reinald, Marie Laurent, Lola Corsin, Nicolas Hoertel, Mathilde Gisselbrecht, Elise Mercadier, Pascaline Boudou-Rouquette, Anne Chahwakilian, Sylvie Bastuji-Garin, Frédéric Limosin, Cédric Lemogne, Florence Canouï-Poitrine, on behalf of the ELCAPA Study Group

The Oncologist first published on December 31, 2018; doi:10.1634/theoncologist.2018-0322

Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer

Elisabetta Pietri, Ilaria Massa, Sara Bravaccini, Sara Ravaioli, Maria Maddalena Tumedei, Elisabetta Petracci, Caterina Donati, Alessio Schirone, Federico Piacentini, Lorenzo Gianni, Mario Nicolini, Enrico Campadelli, Alessandra Gennari, Alessandro Saba, Beatrice Campi, Linda Valmorri, Daniele Andreis, Francesco Fabbri, Dino Amadori, Andrea Rocca

The Oncologist first published on December 27, 2018; doi:10.1634/theoncologist.2018-0243

Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials

José Pérez-Garcia, Javier Cortés, Otto Metzger Filho

The Oncologist first published on December 21, 2018; doi:10.1634/theoncologist.2018-0182

Long-Term Gynecological Cancer Survivors in Côte d'Or: Health-Related Quality of Life and Living Conditions

Ariane Mamguem Kamga, Agnés Dumas, Florence Joly, Oumar Billa, Julien Simon, Marie-Laure Poillot, Ariane Darut-Jouve, Charles Coutant, Pierre Fumoleau, Patrick Arveux, Tienhan Sandrine Dabakuyo-Yonli

The Oncologist first published on December 21, 2018; doi:10.1634/theoncologist.2018-0347

Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial

Carl-Henrik Shah, Helle Pappot, Mads Agerbæk, Karin Holmsten, Fredrik Jäderling, Jeffrey Yachnin, Per Grybäck, Hans von der Maase, Anders Ullén

The Oncologist first published on December 14, 2018; doi:10.1634/theoncologist.2018-0795

Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study

Giovanni Fucá, Nadia Hindi, Isabelle Ray-Coquard, Vittoria Colia, Angelo Paolo Dei Tos, Javier Martin-Broto, Mehdi Brahmi, Paola Collini, Domenica Lorusso, Francesco Raspagliesi, Maria Abbondanza Pantaleo, Bruno Vincenzi, Elena Fumagalli, Alessandro Gronchi, Paolo Giovanni Casali, Roberta Sanfilippo

The Oncologist first published on December 5, 2018; doi:10.1634/theoncologist.2018-0338

How Does a Supervised Exercise Program Improve Quality of Life in Patients with Cancer? A Concept Mapping Study Examining Patients' Perspectives

Maike G. Sweegers, Laurien M. Buffart, Wouke M. van Veldhuizen, Edwin Geleijn, Henk M.W. Verheul, Johannes Brug, Mai J.M. Chinapaw, Teatske M. Altenburg

The Oncologist first published on November 13, 2018; doi:10.1634/theoncologist.2017-0613

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE

Silvana Leo, Ermenegildo Arnoldi, Lazzaro Repetto, Zaira Coccorullo, Saverio Cinieri, Palma Fedele, Marina Cazzaniga, Vito Lorusso, Agnese Latorre, Giovanna Campanella, Mariangela Ciccarese, Caterina Accettura, Salvatore Pisconti, Antonio Rinaldi, Cosimo Brunetti, Mimma Raffaele, Luigi Coltelli, Salvatore Spazzapan, Lucia Fratino, Luciana Petrucelli, Laura Biganzoli

The Oncologist first published on November 9, 2018; doi:10.1634/theoncologist.2017-0676

Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS)

Javier Martin-Broto, Nadia Hindi, Josefina Cruz, Javier Martinez-Trufero, Claudia Valverde, Luis M. De Sande, Angeles Sala, Lorena Bellido, Ana De Juan, Jordi Rubió-Casadevall, Roberto Diaz-Beveridge, Ricardo Cubedo, Oscar Tendero, Diego Salinas, Isidro Gracia, Rafael Ramos, Silvia Baguè, Antonio Gutierrez, José Duran-Moreno, Antonio Lopez-Pousa

The Oncologist first published on November 8, 2018; doi:10.1634/theoncologist.2018-0121

Symptom Expression in Patients with Advanced Cancer Admitted to an Acute Supportive/Palliative Care Unit With and Without Delirium

Sebastiano Mercadante, Claudio Adile, Patrizia Ferrera, Andrea Cortegiani, Alessandra Casuccio

The Oncologist first published on October 24, 2018; doi:10.1634/theoncologist.2018-0244

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma

Alba A. Brandes, Miguel Gil-Gil, Frank Saran, Antoine F. Carpentier, Anna K. Nowak, Warren Mason, Vittorina Zagonel, François Dubois, Gaetano Finocchiaro, George Fountzilas, Dana Michaela Cernea, Oliver Chinot, Rodica Anghel, Francois Ghiringhelli, Patrick Beauchesne, Giuseppe Lombardi, Enrico Franceschi, Martina Makrutzki, Chiedzo Mpofu, Hans-Joerg Urban, Josef Pichler

The Oncologist first published on September 28, 2018; doi:10.1634/theoncologist.2018-0290

Cosmetic Consequences of Breast-Conserving Treatment for Breast Cancer: Something Worth Talking About

Angelique Brands-Appeldoorn, Sabrina Maaskant-Braat, Karin Schenk, Rudi Roumen

The Oncologist first published on September 26, 2018; doi:10.1634/theoncologist.2017-0443

Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors

Sebastien Gouy, Alexandra Arfi, Amandine Maulard, Patricia Pautier, Enrica Bentivegna, Alexandra Leary, Cyrus Chargari, Catherine Genestie, Philippe Morice

The Oncologist first published on September 10, 2018; doi:10.1634/theoncologist.2017-0632

“I need to know what makes somebody tick …”: Challenges and Strategies of Implementing Shared Decision-Making in Individualized Oncology

Joschka Haltaufderheide, Sebastian Wäscher, Bernhard Bertlich, Jochen Vollmann, Anke Reinacher-Schick, Jan Schildmann

The Oncologist first published on September 6, 2018; doi:10.1634/theoncologist.2017-0615

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

Eric Van Cutsem, Erika Martinelli, Stefano Cascinu, Alberto Sobrero, Maria Banzi, Jean-François Seitz, Carlo Barone, Marc Ychou, Marc Peeters, Baruch Brenner, Ralf Dieter Hofheinz, Evaristo Maiello, Thierry André, Andrea Spallanzani, Rocio Garcia-Carbonero, Yull E. Arriaga, Udit Verma, Axel Grothey, Christian Kappeler, Ashok Miriyala, Joachim Kalmus, Alfredo Falcone, Alberto Zaniboni

The Oncologist first published on September 6, 2018; doi:10.1634/theoncologist.2018-0072

Minimal Increase in Survival Throughout the Years in Patients with Soft Tissue Sarcoma with Synchronous Metastases: Results of a Population-Based Study

Melissa Vos, Vincent K. Y. Ho, Astrid W. Oosten, Cornelis Verhoef, Stefan Sleijfer

The Oncologist first published on on September 6, 2018; doi:10.1634/theoncologist.2017-0383

Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe

Eduard Vrdoljak, Gyorgy Bodoky, Jacek Jassem, Razvan Popescu, Robert Pirker, Tanja Čufer, Semir Bešlija, Alexandru Eniu, Vladimir Todorović, Katerina Kopećková, Galia Kurteva, Zorica Tomaševič, Agim Sallaku, Snezhana Smichkoska, Žarko Bajić, Branimir Sikic

The Oncologist first published on September 4, 2018; doi:10.1634/theoncologist.2018-0093

Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs

Barbara Kiesewetter, Heying Duan, Wolfgang Lamm, Alexander Haug, Philipp Riss, Andreas Selberherr, Christian Scheuba, Markus Raderer

The Oncologist first published on on August 31, 2018; doi:10.1634/theoncologist.2018-0191

The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma

Emiliano Calvo, Camillio Porta, Viktor Grünwald, Bernard Escudier

The Oncologist first published on August 29, 2018; doi:10.1634/theoncologist.2018-0267

Definitive Radiotherapy in Invasive Vaginal Carcinoma: A Systematic Review

Consuelo Buttigliero, Frances A. Shepherd, Fabrice Barlesi, Brian Schwartz, Sergey Orlov, Adolfo G. Favaretto, Armando Santoro, Vera Hirsh, Rodryg Ramlau, Adele R. Blackler, Joanna Roder, David Spigel, Silvia Novello, Wallace Akerley, Giorgio V. Scagliotti

The Oncologist first published on August 23, 2018; doi:10.1634/theoncologist.2017-0546

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Consuelo Buttigliero, Frances A. Shepherd, Fabrice Barlesi, Brian Schwartz, Sergey Orlov, Adolfo G. Favaretto, Armando Santoro, Vera Hirsh, Rodryg Ramlau, Adele R. Blackler, Joanna Roder, David Spigel, Silvia Novello, Wallace Akerley, Giorgio V. Scagliotti

The Oncologist first published on August 23, 2018; doi:10.1634/theoncologist.2018-0089

Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib

César Serrano, Xavier García-del-Muro, Claudia Valverde, Ana Sebio, José Durán, Aránzazu Manzano, Isabel Pajares, Nadia Hindi, Stefania Landolfi, Laura Jiménez, Jordi Rubió-Casadevall, Anna Estival, Javier Lavernia, María José Safont, Carles Pericay, Roberto Díaz-Beveridge, Virginia Martínez-Marín, David Vicente-Baz, Ana Vivancos, Javier Hernández-Losa, Joaquín Arribas, Joan Carles

The Oncologist first published on August 20, 2018; doi:10.1634/theoncologist.2018-0032

Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?

Fotios Loupakis, Marta Schirripa, Rossana Intini, Francesca Bergamo, Roberta Bertorelle, Matteo Fassan, Vincenzo Dadduzio, Stefano Merigliano, Pierluigi Pilati, Emanuele Luca Damiano Urso, Umberto Cillo, Massimo Rugge, Sara Lonardi, Vittorina Zagonel

The Oncologist first published on August 17, 2018;doi:10.1634/theoncologist.2018-0180

Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

Pilar García-Alfonso, Manuel Benavides, Esther Falcó, Andrés Muñoz, Auxiliadora Gómez, Javier Sastre, Fernando Rivera, Clara Montagut, Mercedes Salgado, Amelia López-Ladrón, Rafael López, Inmaculada Ruiz de Mena, Gema Durán, Enrique Aranda, on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)

The Oncologist first published on August 17, 2018; doi:10.1634/theoncologist.2018-0316

Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology

Gaia Griguolo, Stephane Pouderoux, Maria Vittoria Dieci, William Jacot, Céline Bourgier, Federica Miglietta, Nelly Firmin, Pierfranco Conte, Marie Viala, Valentina Guarneri, Amélie Darlix

The Oncologist first published on August 17, 2018; doi:10.1634/theoncologist.2018-0200

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study

Konstantinos Syrigos, Dimitra Grapsa, Rabiatou Sangare, Ilias Evmorfiadis, Annette K. Larsen, Patrick Van Dreden, Paraskevi Boura, Andriani Charpidou, Elias Kotteas, Theodoros N. Sergentanis, Ismail Elalamy, Anna Falanga, Grigoris T. Gerotziafas

The Oncologist first published on August 13, 2018; doi:10.1634/theoncologist.2017-0530

Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA

Matteo Franchi, Sandro Barni, Giovanna Tagliabue, Paolo Ricci, Walter Mazzucco, Rosario Tumino, Antonietta Caputo, Giovanni Corrao, on behalf of the GRETA working group

The Oncologist first published on August 10, 2018; doi:10.1634/theoncologist.2017-0314

NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancerp

Vanesa Gregorc, Raffaele Cavina, Sivia Novello, Francesco Grossi, Chiara Lazzari, Enrica Capelletto, Carlo Genova, Giulia Salini, Antonio Lambiase, Armando Santoro

The Oncologist first published on August 3, 2018; doi:10.1634/theoncologist.2018-0292

Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group

Ales Ryska, Rares Buiga, Albena Fakirova, Izidor Kern, Włodzimierz Olszewski, Lukas Plank, Sven Seiwerth, Erika Toth, Eri Zivka, Christiane Thallinger, Christoph Zielinski, Luka Brcic

The Oncologist first published on August 3, 2018; doi:10.1634/theoncologist.2018-0008

Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma

Shai Rosenberg, Francois Ducray, Agusti Alentorn, Caroline Dehais, Nabila Elarouci, Aurelie Kamoun, Yannick Marie, Marie-Laure Tanguy, Aurélien De Reynies, Karima Mokhtari, Dominique Figarella-Branger, Jean-Yves Delattre, Ahmed Idbaih, POLA Network

The Oncologist 2018 first published on July 17, 2018; doi:10.1634/theoncologist.2017-0495

Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study

Mariette Labots, Johannes C. Van der Mijn, Henk Dekker, Rita Ruijter, Thang V. Pham, Hans J. Van der Vliet, Jacobus J.M. Van der Hoeven, Gerrit A. Meijer, Henk M.W. Verheul

The Oncologist 2018 first published on July 17, 2018; doi:10.1634/theoncologist.2018-0263

Training for Medical Oncologists on Shared Decision-Making About Palliative Chemotherapy: A Randomized Controlled Trial

Inge Henselmans, Hanneke W.M. van Laarhoven, Hanneke C.J.M. de Haes, Meltem Tokat, Ellen G. Engelhardt, Pomme E.A. van Maarschalkerweerd, Marleen Kunneman, Petronella B. Ottevanger, Serge E. Dohmen, Geert-Jan Creemers, Dirkje W. Sommeijer, Filip Y.F.L. de Vos, Ellen M.A. Smets

The Oncologist first published on June 29, 2018; doi:10.1634/theoncologist.2018-0090

Cognitive Changes After Adjuvant Treatment in Older Adults with Early-Stage Breast Cancer

Marie Lange, Natacha Heutte, Sabine Noal, Olivier Rigal, Jean-Emmanuel Kurtz, Christelle Lévy, Djelila Allouache, Chantal Rieux, Johan Lefel, Bénédicte Clarisse, Alexandra Leconte, Corinne Veyret, Philippe Barthélémy, Nadine Longato, Laure Tron, Hélène Castel, Francis Eustache, Bénédicte Giffard, Florence Joly

The Oncologist first published on June 22, 2018; doi:10.1634/theoncologist.2017-0570

Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)

Loïc Chaigneau, Anna Patrikidou, Isabelle Ray-Coquard, Thibaud Valentin, Claude Linassier, Jacques Olivier Bay, Laurence Moureau Zabotto, Emmanuelle Bompas, Sophie Piperno-Neumann, Nicolas Penel, Thierry Alcindor, Maryline Laigre, Cecile Guillemet, Sebastien Salas, Anne Hugli, Julien Domont, Marie Pierre Sunyach, Axel Lecesne, Jean Yves Blay, Virginie Nerich, Nicolas Isambert

The Oncologist 2018 first published on June 22, 2018; doi:10.1634/theoncologist.2017-0136

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

Jaume Capdevila, Alexandre Teulé, Jorge Barriuso, Daniel Castellano, Carlos Lopez, Jose Luis Manzano, Vicente Alonso, Rocío García-Carbonero, Emma Dotor, Ignacio Matos, Ana Custodio, Oriol Casanovas, Ramon Salazar, on behalf of the EVERLAR study investigators

The Oncologist first published on May 23, 2018; doi:10.1634/theoncologist.2017-0622

Personalized Symptom Goals and Patient Global Impression on Clinical Changes in Advanced Cancer Patients

Sebastiano Mercadante, Claudio Adile, Gaetano Lanzetta, Kyriaki Mystakidou, Marco Maltoni, Luiz Guilherme Soares, Stefano De Santis, Patrizia Ferrera, Marco Valenti, Marta Rosati, Romina Rossi, Andrea Cortegiani, Francesco Masedu, Franco Marinangeli, Federica Aielli

The Oncologist first published on May 16, 2018; doi:10.1634/theoncologist.2017-0668

Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program

Chiara Cremolini, Daniele Rossini, Erika Martinelli, Filippo Pietrantonio, Sara Lonardi, Silvia Noventa, Emiliano Tamburini, Giovanni Luca Frassineti, Stefania Mosconi, Federico Nichetti, Sabina Murgioni, Teresa Troiani, Beatrice Borelli, Gemma Zucchelli, Alessandro Dal Maso, Vincenzo Sforza, Gianluca Masi, Carlotta Antoniotti, Maria Di Bartolomeo, Rosalba Miceli, Fortunato Ciardiello, Alfredo Falcone

The Oncologist first published on May 8, 2018; doi:10.1634/theoncologist.2017-0573

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab

Asunción Díaz-Serrano, Barbara Angulo, Carolina Dominguez, Roberto Pazo-Cid, Antonieta Salud, Paula Jiménez-Fonseca, Ana Leon, Maria Carmen Galan, Maria Alsina, Fernando Rivera, J. Carlos Plaza, Luis Paz-Ares, Fernando Lopez-Rios, Carlos Gómez-Martín

The Oncologist first published on April 26, 2018; doi:10.1634/theoncologist.2017-0379

Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall? 

Pellegrino Musto

The Oncologist 2018; 23:511-515; first published on April 26, 2018; doi:10.1634/theoncologist.2018-0097

Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study)

Vittorio Stefoni, Cinzia Pellegrini, Alessandro Broccoli, Luca Baldini, Monica Tani, Emanuele Cencini, Amalia Figuera, Michela Ansuinelli, Elisa Bernocco, Maria Cantonetti, Maria Christina Cox, Filippo Ballerini, Chiara Rusconi, Carlo Visco, Luca Arcaini, Angelo Fama, Roberto Marasca, Stefano Volpetti, Alessia Castellino, Catello Califano, Marina Cavaliere, Guido Gini, Anna Marina Liberati, Gerardo Musuraca, Anna Lucania, Giuseppina Ricciuti, Lisa Argnani, Pier Luigi Zinzani

The Oncologist first published on April 19, 2018; doi:10.1634/theoncologist.2017-0597

Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials

Eugenie Younger, Saskia Litière, Axel Le Cesne, Olivier Mir, Hans Gelderblom, Antoine Italiano, Sandrine Marreaud, Robin Lewis Jones, Alessandro Gronchi, Winette T.A. van der Graaf

The Oncologist first published on April 12, 2018; doi:10.1634/theoncologist.2017-0598

Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison

Nina C.A. Vermeer, Yvette H.M. Claassen, Marloes G.M. Derks, Lene H. Iversen, Elizabeth van Eycken, Marianne G. Guren, Pawel Mroczkowski, Anna Martling, Robert Johansson, Tamara Vandendael, Arne Wibe, Bjorn Moller, Hans Lippert, Johanneke E.A. Portielje, Gerrit Jan Liefers, Koen C.M.J. Peeters, Cornelis J.H. van de Velde, Esther Bastiaannet

The Oncologist first published on March 22, 2018; doi:10.1634/theoncologist.2017-0551

Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03)

Carmine Pinto, Maurizio Di Bisceglie, Francesca Di Fabio, Annamaria Bochicchio, Tiziana Latiano, Stefano Cordio, Gerardo Rosati, Carlo Aschele, Antonella Marino, Francesca Bergamo, Sara Bustreo, Luca Frassineti, Fortunato Ciardiello, Angela Damato, Stefania Giaquinta, Daniela Baldari, Luca Boni

The Oncologist first published on March 9, 2018; doi:10.1634/theoncologist.2017-0484

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

Germán Reyes-Botero, Stéphanie Cartalat-Carel, Olivier L. Chinot, Maryline Barrie, Luc Taillandier, Patrick Beauchesne, Isabelle Catry-Thomas, Jérôme Barrière, Jean-Sebastien Guillamo, Michel Fabbro, Didier Frappaz, Alexandra Benouaich-Amiel, Emilie Le Rhun, Chantal Campello, Isabelle Tennevet, François Ghiringhelli, Marie-Laure Tanguy, Karima Mokhtari, Jérôme Honnorat, Jean-Yves Delattre

The Oncologist first published on February 22, 2018; doi:10.1634/theoncologist.2017-0689

Panobinostat and Multiple Myeloma in 2018

Andrew J. Yee, Noopur S. Raje

The Oncologist 2018; 23:516-517; first published on February 14, 2018; doi:10.1634/theoncologist.2017-0644

Early Gastric Cancer: Clinical Behavior and Treatment Options. Results of an Italian Multicenter Study on Behalf of the Italian Gastric Cancer Research Group (GIRCG)

Luca Saragoni, Emanuela Scarpi, Alessandra Ravaioli, Paolo Morgagni, Franco Roviello, Carla Vindigni, Stefano Rausei, Anna Maria Chiaravalli, Uberto Fumagalli, Paola Spaggiari, Fausto Rosa, Riccardo Ricci, Annibale Donini, Paolo Giovenali, Anna Tomezzoli, Giovanni De Manzoni

The Oncologist first published on January 31, 2018; doi:10.1634/theoncologist.2017-0488

EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma

Kyriaki Tzogani, Elisabeth Penninga, Marie Louise Schougaard Christiansen, Doris Hovgaard, Sinan B. Sarac, Jorge Camarero Jimenez, Isabel Garcia, Marta Lafuente, Arantxa Sancho-López, Tomas Salmonson, Christian Gisselbrecht, Francesco Pignatti

The Oncologist first published on January 25, 2018; doi:10.1634/theoncologist.2017-0328

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (RGETNE)

Barbara Nuñez-Valdovinos, Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, Jaume Capdevila, Ángel Castaño-Pascual, Marta Benavent, Jose Javier Pi Barrio, Alex Teule, Vicente Alonso, Ana Custodio, Monica Marazuela, Ángel Segura, Adolfo Beguiristain, Marta Llanos, Maria Purificacion Martinez del Prado, Jose Angel Diaz-Perez, Daniel Castellano, Isabel Sevilla, Carlos Lopez, Teresa Alonso, Rocio Garcia-Carbonero

The Oncologist 2018; 23:422-432; first published on January 12, 2018; doi:10.1634/theoncologist.2017-0364

Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies

Nadia Harbeck, Pere Gascón, Andriy Krendyukov, Nadja Hoebel, Sreekanth Gattu, Kimberly Blackwell

The Oncologist 2018; 23:403-409; first published on January 9, 2018; doi:10.1634/theoncologist.2017-0348

Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study

Patrizia Mondello, Normann Steiner, Wolfgang Willenbacher, Claudio Cerchione, Davide Nappi, Endri Mauro, Simone Ferrero, Salvatore Cuzzocrea, Michael Mian

The Oncologist 2018; 23:454-460; first published on January 9, 2018; doi:10.1634/theoncologist.2017-0037

Fertility-Sparing Treatment of Endometrial Cancer with Initial Infiltration of Myometrium by Resectoscopic Surgery: A Pilot Study

Paolo Casadio, Francesca Guasina, Roberto Paradisi, Concetta Leggieri, Giacomo Caprara, Renato Seracchioli

The Oncologist 2018; 23:478-480; first published on January 9, 2018; doi:10.1634/theoncologist.2017-0285

Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers

Sebastien Gouy, Marine Saidani, Amandine Maulard, Slim Bach-Hamba, Enrica Bentivegna, Alexandra Leary, Patricia Pautier, Mojgan Devouassoux-Shisheboran, Catherine Genestie, Philippe Morice

The Oncologist 2018; 23:324-327; first published on December 14, 2017; doi:10.1634/theoncologist.2017-0310

FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation

Lauretta Odogwu, Luckson Mathieu, Kirsten B. Goldberg, Gideon M. Blumenthal, Erin Larkins, Mallorie H. Fiero, Lisa Rodriguez, Karen Bijwaard, Eunice Y. Lee, Reena Philip, Ingrid Fan, Martha Donoghue, Patricia Keegan, Amy McKee, Richard Pazdur

The Oncologist first published on December 14, 2017; doi:10.1634/theoncologist.2017-0425

Successful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon-α

Smaranda Gazdaru, Lucien Perey, Anne Rosselet, Patrice Mathevet, Yves Chalandon, Nicolas Vulliemoz

The Oncologist 2018; 23:719-721; first published on December 6, 2017; doi:10.1634/theoncologist.2017-0381

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma

Kyriaki Tzogani, Paula van Hennik, Ita Walsh, Pieter De Graeff, Annika Folin, Jan Sjöberg, Tomas Salmonson, Jonas Bergh, Edward Laane, Heinz Ludwig, Christian Gisselbrecht, Francesco Pignatti

The Oncologist first published on November 30, 2017; doi:10.1634/theoncologist.2017-0301

Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison

Suzy Van Sanden, Tetsuro Ito, Joris Diels, Martin Vogel, Andrew Belch, Albert Oriol

The Oncologist 2018; 23:279-287; first published on November 30, 2017; doi:10.1634/theoncologist.2017-0103

Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey

Christian Rothermundt, Galina F. Fischer, Sebastian Bauer, Jean-Yves Blay, Viktor Grünwald, Antoine Italiano, Bernd Kasper, Attila Kollár, Lars H. Lindner, Aisha Miah, Stefan Sleijfer, Silvia Stacchiotti, Paul Martin Putora

The Oncologist 2018; 23:461-467; first published on November 30, 2017; doi:10.1634/theoncologist.2017-0391

Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma

Manuela Schmidinger, Romano Danesi

The Oncologist 2018; 23:306-315; first published on November 16, 2017; doi:10.1634/theoncologist.2017-0335

"Rather one more chemo than one less...": Oncologists and Oncology Nurses' Reasons for Aggressive Treatment of Young Adults with Advanced Cancer

Katsiaryna Laryionava, Pia Heußner, Wolfgang Hiddemann, Eva C. Winkler

The Oncologist 2018; 23:256-262; first published on November 13, 2017; doi:10.1634/theoncologist.2017-0094

Quality of Randomized Controlled Trials Reporting in the Treatment of Adult Patients with High-Grade Gliomas

Magalie P. Tardy, Jocelyn Gal, Emmanuel Chamorey, Fabien Almairac, Fanny Vandenbos, Pierre-Yves Bondiau, Esma Saada-Bouzid

The Oncologist 2018; 23:337-345; first published on November 13, 2017; doi:10.1634/theoncologist.2017-0196

Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms

Maria Rinzivillo, Stefano Partelli, Daniela Prosperi, Gabriele Capurso, Patrizia Pizzichini, Elsa Iannicelli, Elettra Merola, Francesca Muffatti, Francesco Scopinaro, Orazio Schillaci, Matteo Salgarello, Massimo Falconi, Gianfranco Delle Fave, Francesco Panzuto

The Oncologist 2018; 23:186-192; first published on November 8, 2017; doi:10.1634/theoncologist.2017-0278

Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma

Douwe Postmus, Sarah Richard, Nathalie Bere, Gert van Valkenhoef, Jayne Galinsky, Eric Low, Isabelle Moulon, Maria Mavris, Tomas Salmonsson, Beatriz Flores, Hans Hillege, Francesco Pignatti

The Oncologist 2018; 23:44-51; first published on October 27, 2017; doi:10.1634/theoncologist.2017-0257

A Clinical and Biological Guide for Understanding Chemotherapy-Induced Alopecia and Its Prevention


Christopher John Dunnill, Wafaa Al-Tameemi, Andrew Collett, Iain Stuart Haslam, Nikolaos Theodoros Georgopoulos

The Oncologist 2018; 23:84-96; first published on September 26, 2017; doi:10.1634/theoncologist.2017-0263

The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

Kyriaki Tzogani, Jorge Camarero Jiménez, Isabel Garcia, Arantxa Sancho-López, Marc Martin, Alexandre Moreau, Pierre Demolis, Tomas Salmonson, Jonas Bergh, Edward Laane, Heinz Ludwig, Christian Gisselbrecht, Francesco Pignatti

The Oncologist 2017; 22:1339-1346; first published on September 21, 2017; doi:10.1634/theoncologist.2017-0184

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy

Valentina Fanotto, Mario Uccello, Irene Pecora, Lorenza Rimassa, Francesco Leone, Gerardo Rosati, Daniele Santini, Riccardo Giampieri, Samantha Di Donato, Gianluca Tomasello, Nicola Silvestris, Filippo Pietrantonio, Francesca Battaglin, Antonio Avallone, Mario Scartozzi, Eufemia Stefania Lutrino, Davide Melisi, Lorenzo Antonuzzo, Antonio Pellegrino, Laura Ferrari, Roberto Bordonaro, Caterina Vivaldi, Lorenzo Gerratana, Silvia Bozzarelli, Roberto Filippi, Domenico Bilancia, Marco Russano, Giuseppe Aprile

The Oncologist 2017; 22:1463-1469; first published on August 31, 2017; doi:10.1634/theoncologist.2017-0158

Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials

Alessandro Comandone, Fausto Petrelli, Antonella Boglione, Sandro Barni

The Oncologist 2017; 22:1518-1527; first published on August 23, 2017; doi:10.1634/theoncologist.2016-0474

Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma

Silvia Stacchiotti, Olivier Mir, Axel Le Cesne, Bruno Vincenzi, Alexander Fedenko, Robert G. Maki, Neeta Somaiah, Shreyaskumar Patel, Mehedi Brahmi, Jean Y. Blay, Kjetil Boye, Kirsten Sundby Hall, Hans Gelderblom, Nadia Hindi, Javier Martin-Broto, Hanna Kosela, Piotr Rutkowski, Antoine Italiano, Florence Duffaud, Eisuke Kobayashi, Paolo G. Casali, Salvatore Provenzano, Akira Kawai

The Oncologist 2018; 23:62-70; first published on July 28, 2017; doi:10.1634/theoncologist.2017-0161

Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis

Miguel Martín, José I. Chacón, Antonio Antón, Arrate Plazaola, Elena García-Martínez, Miguel A. Seguí, Pedro Sánchez-Rovira, José Palacios, Lourdes Calvo, Carmen Esteban, Enrique Espinosa, Agusti Barnadas, Norberto Batista, Angel Guerrero, Montserrat Muñoz, Estefania Romio, César Rodríguez-Martín, Rosalía Caballero, María I. Casas, Federico Rojo, Eva Carrasco, Silvia Antolín

The Oncologist 2017; 22:1301-1308; first published on July 12, 2017; doi:10.1634/theoncologist.2017-0052

Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results

Alessandro Passardi, Francesca Fanini, Livia Turci, Flavia Foca, Paola Rosetti, Silvia Ruscelli, Andrea Casadei Gardini, Martina Valgiusti, Claudio Dazzi, Maurizio Marangolo

The Oncologist 2017; 22:886-e79; first published on June 7, 2017; doi:10.1634/theoncologist.2017-0206

Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer

Marco Siano, Francesca Molinari, Vittoria Martin, Nicolas Mach, Martin Früh, Stefania Freguia, Irene Corradino, Michele Ghielmini, Milo Frattini, Vittoria Espeli

The Oncologist 2017; 22:782-e70; first published on June 7, 2017; doi:10.1634/theoncologist.2017-0069

Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation

Aristotle Bamias, Bernard Escudier, Cora N. Sternberg, Flora Zagouri, Athanasios Dellis, Bob Djavan, Kimon Tzannis, Loukas Kontovinis, Konstantinos Stravodimos, Athanasios Papatsoris, Dionysios Mitropoulos, Charalampos Deliveliotis, Meletios-Athanasios Dimopoulos, Constantine A. Constantinides

The Oncologist 2017; 22:667-679; first published on June 7, 2017; doi:10.1634/theoncologist.2016-0435

A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer

Cristian Lolli, Valentina Gallà, Giuseppe Schepisi, Domenico Barone, Salvatore Luca Burgio, Antonio Maugeri, Bernadette Vertogen, Dino Amadori, Ugo De Giorgi

The Oncologist 2017; 22:784-e74; first published on May 25, 2017; doi:10.1634/theoncologist.2017-0154

Accessibility, Availability, and Potential Benefits of Psycho-Oncology Services: The Perspective of Community-Based Physicians Providing Cancer Survivorship Care

Verena Zimmermann-Schlegel, Mechthild Hartmann, Halina Sklenarova, Wolfgang Herzog, Markus W. Haun

The Oncologist 2017; 22:719-727; first published on April 24, 2017; doi:10.1634/theoncologist.2016-0245

Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study

Chiara Alessandra Cella, Giovanni Di Minno, Chiara Carlomagno, Michele Arcopinto, Anna Maria Cerbone, Elide Matano, Antonella Tufano, Florian Lordick, Biagio De Simone, Katja Sibylle Muehlberg, Dario Bruzzese, Laura Attademo, Claudia Arturo, Marta Sodano, Roberto Moretto, Ersilia La Fata, Sabino De Placido

The Oncologist 2017; 22:601-608; first published on April 19, 2017; doi:10.1634/theoncologist.2016-0246

Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma

Marco Skardelly, Elena Dangel, Julia Gohde, Susan Noell, Felix Behling, Guilherme Lepski, Christian Borchers, Marilin Koch, Jens Schittenhelm, Sotirios Bisdas, Aline Naumann, Frank Paulsen, Daniel Zips, Ulrike von Hehn, Rainer Ritz, Marcos Soares Tatagiba, Ghazaleh Tabatabai

The Oncologist 2017; 22:570-575; first published on March 30, 2017; doi:10.1634/theoncologist.2016-0347

Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin

Jacopo Olivieri, Gian Piero Perna, Caterina Bocci, Claudia Montevecchi, Attilio Olivieri, Pietro Leoni, Guido Gini

The Oncologist 2017; 22:422-431; first published on March 8, 2017; doi:10.1634/theoncologist.2016-0289

Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications

Alba A. Brandes, Enrico Franceschi, Alexandro Paccapelo, Giovanni Tallini, Dario De Biase, Claudio Ghimenton, Daniela Danieli, Elena Zunarelli, Giovanni Lanza, Enrico Maria Silini, Carmelo Sturiale, Lorenzo Volpin, Franco Servadei, Andrea Talacchi, Antonio Fioravanti, Maria Pia Foschini, Stefania Bartolini, Annalisa Pession, Mario Ermani

The Oncologist 2017; 22:432-437; first published on March 8, 2017; doi:10.1634/theoncologist.2016-0254

Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome

Francesco Panzuto, Elettra Merola, Marianne Ellen Pavel, Anja Rinke, Patrizia Kump, Stefano Partelli, Maria Rinzivillo, Victor Rodriguez-Laval, Ulrich Frank Pape, Rainer Lipp, Thomas Gress, Bertram Wiedenmann, Massimo Falconi, Gianfranco Delle Fave

The Oncologist 2017; 22:409-415; first published on February 23, 2017; doi:10.1634/theoncologist.2016-0351

Management of Cancer in the Older Age Person: An Approach to Complex Medical Decisions

María Vallet-Regí, Miguel Manzano, Leocadio Rodriguez-Mañas, Marta Checa López, Matti Aapro, Lodovico Balducci

The Oncologist 2017; 22:335-342; first published on February 20, 2017; doi:10.1634/theoncologist.2016-0276

Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients

Francesco Sclafani, Federica Morano, David Cunningham, Chiara Baratelli, Eleftheria Kalaitzaki, David Watkins, Naureen Starling, Ian Chau, Sheela Rao

The Oncologist 2017; 22:402-408; first published on February 16, 2017; doi:10.1634/theoncologist.2016-0241

Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany

Peter Dall, Thorsten Koch, Thomas Göhler, Johannes Selbach, Andreas Ammon, Jochen Eggert, Nidal Gazawi, Daniela Rezek, Arthur Wischnik, Carsten Hielscher, Stella Keitel, Ursula Cirrincione, Axel Hinke, Gabriele Feisel-ardi

The Oncologist 2017; 22:131-138; first published on February 7, 2017; doi:10.1634/theoncologist.2016-0193

Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors

Maikel Verduin, Jaap D. Zindler, Hanneke M.A. Martinussen, Rob L.H. Jansen, Sander Croes, Lizza E.L. Hendriks, Danielle B.P. Eekers, Ann Hoeben

The Oncologist 2017; 22:222-235; first published on February 6, 2017; doi:10.1634/theoncologist.2016-0117

Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies

Sander Bins, Geert A. Cirkel, Christa G. Gadellaa-Van Hooijdonk, Fleur Weeber, Isaac J. Numan, Annette H. Bruggink, Paul J. van Diest, Stefan M. Willems, Wouter B. Veldhuis, Michel M. van den Heuvel, Rob J. de Knegt, Marco J. Koudijs, Erik van Werkhoven, Ron H.J. Mathijssen, Edwin Cuppen, Stefan Sleijfer, Jan H.M. Schellens, Emile E. Voest, Marlies H.G. Langenberg, Maja J.A. de Jonge, Neeltje Steeghs, Martijn P. Lolkema

The Oncologist 2017; 22:33-40; first published on September 23, 2016; doi:10.1634/theoncologist.2016-0085

The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Maria Nieto, Pierre Demolis, Eliane Béhanzin, Alexandre Moreau, Ian Hudson, Beatriz Flores, Henry Stemplewski, Tomas Salmonson, Christian Gisselbrecht, David Bowen, Francesco Pignatti

The Oncologist 2016; 21:692-700; first published on April 18, 2016; doi:10.1634/theoncologist.2015-0298

Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors
Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Olga Martínez-Sáez, Enrique Grande

The Oncologist 2016; 21:701-707; first published on April 22, 2016; doi:10.1634/theoncologist.2015-0455

Best Practices in Chronic Myeloid Leukemia Monitoring and Management
Simona Soverini, Caterina De Benedittis, Manuela Mancini, Giovanni Martinelli

The Oncologist 2016; 21:626-633; first published on March 31, 2016; doi:10.1634/theoncologist.2015-0337

Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
Giovanni Brandi, Marzia Deserti, Francesco Vasuri, Andrea Farioli, Alessio Degiovanni, Andrea Palloni, Giorgio Frega, Maria A. Barbera, Stefania de Lorenzo, Ingrid Garajova, Mariacristina Di Marco, Antonio D. Pinna, Matteo Cescon, Alessandro Cucchetti, Giorgio Ercolani, Antonietta D’Errico-Grigioni, Maria A. Pantaleo, Guido Biasco, Simona Tavolari, on behalf of G.I.CO. (Gruppo Italiano Colangiocarcinoma)

The Oncologist 2016; 21:600-607; first published on March 31, 2016; doi:10.1634/theoncologist.2015-0356

Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium
Shanly C. Seferina, Maaike de Boer, M. Wouter Derksen, Franchette van den Berkmortel, Roel J.W. van Kampen, Agnès J. van de Wouw, Manuela Joore, Petronella G.M. Peer, Adri C. Voogd, Vivianne C.G. Tjan-Heijnen

The Oncologist first published Online March 23, 2016; doi:10.1634/theoncologist.2015-0230

Responding to Acute Care Needs of Patients With Cancer: Recent Trends Across Continents
Alison Young, Ernie Marshall, Monika Krzyzanowska, Bridget Robinson, Sean Brown, Fiona Collinson, Jennifer Seligmann, Afroze Abbas, Adrian Rees, Daniel Swinson, Helen Neville-Webbe, Peter Selby

Emergency presentations of cancer patients to health care services can be associated with high risks and poor outcomes. Systematic approaches are described to create best practice for these patients based on expert teams and careful organization of services in all hospitals. These approaches, called “acute oncology” in the U.K., may improve care and avoid unnecessary deaths.


The Oncologist 2016; 21:301-307; first published on February 26, 2016; doi:10.1634/theoncologist.2014-0341

Supplemental Case Discussions

Management of Malignant Ascites in the Acute Oncology Setting
Sean Brown, Helen Neville-Webbe

Treating Cancer Patients With Diabetes: The Need for a Multidisciplinary Approach
Jennifer Seligmann, Afroze Abbas, Adrian Rees, Daniel Swinson

Febrile Neutropenia
Alison C. Young, Fiona J. Collinson

The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective
Jo Caers, Carlos Fernández de Larrea, Xavier Leleu, Roy Heusschen, Niklas Zojer, Olivier Decaux, Efstathios Kastritis, Monique Minnema, Artur Jurczyszyn, Yves Beguin, Ralph Wäsch, Antonio Palumbo, Meletios Dimopoulos, Maria Victoria Mateos, Heinz Ludwig, Monika Engelhardt

Emergency presentations of cancer patients to health care services can be associated with high risks and poor outcomes. Systematic approaches are described to create best practice for these patients based on expert teams and careful organization of services in all hospitals. These approaches, called "acute oncology" in the U.K., may improve care and avoid unnecessary deaths.

The Oncologist 2016; 21:333-342; first published on February 26, 2016; doi:10.1634/theoncologist.2015-0303

Candidate Predictors of Health-Related Quality of Life of Colorectal Cancer Survivors: A Systematic Review
Martijn J.L. Bours, Bernadette W.A. van der Linden, Renate M. Winkels, Fränzel J. van Duijnhoven, Floortje Mols, Eline H. van Roekel, Ellen Kampman, Sandra Beijer, Matty P. Weijenberg

The Oncologist 2016; 21:433-452; first published on February 24, 2016; doi:10.1634/theoncologist.2015-0258

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
Sophie Piperno-Neumann, Alhassane Diallo, Marie-Christine Etienne-Grimaldi, François-Clément Bidard, Manuel Rodrigues, Corine Plancher, Pascale Mariani, Nathalie Cassoux, Didier Decaudin, Bernard Asselain, Vincent Servois

The Oncologist 2016; 21:281-282; first published on February 24, 2016; doi:10.1634/theoncologist.2015-0501

Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT
Sebastian Giebel, Myriam Labopin, Adalberto Ibatici, Paul Browne, Tomasz Czerw, Gerard Socie, Ali Unal, Slawomira Kyrcz-Krzemien, Andrea Bacigalupo, Hakan Goker, Mike Potter, Caroline L. Furness, Grant McQuaker, Dietrich Beelen, Noel Milpied, Antonio Campos, Charles Craddock, Arnon Nagler, Mohamad Mohty

Results of allogeneic hematopoietic cell transplantation (alloHCT) and other advanced oncological procedures may vary among countries and be related to various economic factors. This study, which included a homogenous population of patients with acute lymphoblastic leukemia, demonstrated significant associations of health care expenditure and the Human Development Index with nonrelapse mortality and overall survival after transplantation. The findings should be taken into account when clinical studies in the field of alloHCT are interpreted. The study should be followed by further investigation in other fields of oncology.

The Oncologist 2016; 21:377-383; first published on February 11, 2016; doi:10.1634/theoncologist.2015-0314

Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications
Valeria Simone, Morena D’Avenia, Antonella Argentiero, Claudia Felici, Francesca Maria Rizzo, Giovanni De Pergola, Franco Silvestris

The Oncologist 2016; 21:404-417; first published on February 10, 2016; doi:10.1634/theoncologist.2015-0351

PSA tests on Planet Faraway: The Influence of Our Numerical System on Clinical Practice
Paul Martin Putora, Nikola Cihoric, Jan Oldenburg

Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting
Luisa Carbognin, Sara Pilotto, Rolando Nortilli, Matteo Brunelli, Alessia Nottegar, Isabella Sperduti, Diana Giannarelli, Emilio Bria, Giampaolo Tortora

The Oncologist 2016; 21:283-291; first published on February 10, 2016; doi:10.1634/theoncologist.2015-0307

Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms
Christian Martin Kurbacher, Olympia Horn, Jutta Anna Kurbacher, Susanne Herz, Ann Tabea Kurbacher, Ralf Hildenbrand, Reinhardt Bollmann

Catumaxomab (CATU) is a trifunctional antibody approved for intraperitoneal (i.p.) treatment of malignant ascites (MA) related to carcinomas expressing the epithelial cell-adhesion molecule (EpCAM). CATU is mostly given to hospitalized patients, although outpatient treatment seems appropriate in selected individuals. This observational trial sought to obtain more detailed information regarding the feasibility of CATU in outpatients with MA related to various gynecologic tumors, including epithelial ovarian (EOC) and metastatic breast cancer (MBC).< /p>

The Oncologist 2015; 20:1333-1341; first published on September 28, 2015; doi:10.1634/theoncologist.2015-0076

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors
David F. Heigener, Christian Schumann, Martin Sebastian, Parvis Sadjadian, Ingo Stehle, Angela Märten, Anne Lüers, Frank Griesinger, Matthias Scheffler, for the Afatinib Compassionate Use Consortium (ACUC)

Afatinib is clinically active and well tolerated in many TKI-pretreated NSCLC patients harboring uncommon EGFR mutations. Compared with results reported in TKI-naïve patients, activity was also indicated in patients with T790M and exon 20 insertion mutations.

The Oncologist 2015; 20:1167-1174; first published on September 9, 2015; doi:10.1634/theoncologist.2015-0073

Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram
Agnese Barnabei, Lidia Strigari, Paolo Marchetti, Valentina Sini, Liana De Vecchis, Salvatore Maria Corsello, Francesco Torino

The meta-analysis of data pooled from the selected studies showed that both age and serum AMH are reliable predictors of post-treatment ovarian activity in breast cancer patients. Importantly, ROC/AUC analysis indicated AMH was a more reliable predictor of post-treatment ovarian activity in patients aged younger than 40 years (0.753; 95% confidence interval [CI]: 0.602–0.904) compared with those older than 40 years (0.678; 95% CI: 0.491–0.866). We generated a nomogram describing the correlations among age, pretreatment AMH serum levels, and ovarian activity at 1 year from the end of chemotherapy.

The Oncologist 2015; 20:1111-1118; first published on September 4, 2015; doi:10.1634/theoncologist.2015-0183

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41)
Amie E. Jackson, Michael Mian, Christina Kalpadakis, Gerassimos A. Pangalis, Anastasios Stathis, Elena Porro, Annarita Conconi, Sergio Cortelazzo, Gianluca Gaidano, Armando Lopez, Guillermo, Peter W. Johnson, Maurizio Martelli, Giovanni Martinelli, Catherine Thieblemont, Ellen D. McPhail, Christiane Copie-Bergman, Stefano A. Pileri, Andrew Jack, Elias Campo, Luca Mazzucchelli, Kay Ristow, Thomas M. Habermann, Franco Cavalli, Grzegorz S. Nowakowski, Emanuele Zucca

Salivary gland MALT lymphoma has an excellent prognosis regardless of initial treatment, and patients with Sjögren disease have improved survival. Risks for long-term complications must be weighed when determining initial therapy.
The Oncologist 2015; 20:1149-1153; first published on August 12, 2015; doi:10.1634/theoncologist.2015-0180

Perspectives of Medical Specialists on Sharing Decisions in Cancer Care: A Qualitative Study Concerning Chemotherapy Decisions With Patients With Recurrent Glioblastoma
Janine C. De Snoo-Trimp, Linda Brom, H. Roeline W. Pasman, Bregje D. Onwuteaka-Philipsen, Guy A.M. Widdershoven

Medical specialists recognized the importance of patient involvement but experienced difficulty in sharing decision making in practice. Elements of shared decision making are partly followed but do not guide decision making. To improve cancer care, education of medical specialists and adjustment to the elements are needed to involve patients.
The Oncologist 2015; 20:1182-1188; first published on August 5, 2015; doi:10.1634/theoncologist.2015-0095

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer
Valentina Guarneri, Maria Vittoria Dieci, Antonio Frassoldati, Antonino Maiorana, Guido Ficarra, Stefania Bettelli, Enrico Tagliafico, Silvio Bicciato, Daniele Giulio Generali, Katia Cagossi, Giancarlo Bisagni, Samanta Sarti, Antonino Musolino, Catherine Ellis, Rocco Crescenzo, PierFranco Conte

PIK3CA mutations seem to identify patients who are less likely to benefit from dual anti-HER2 inhibition. p95-HER2 and markers of phosphoinositide 3-kinase pathway deregulation are not confirmed as markers of different sensitivity to trastuzumab or lapatinib.
The Oncologist 2015; 20:1001-1010; first published on August 5, 2015; doi:10.1634/theoncologist.2015-0138

Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study
Joseph Gligorov, Xavier B. Pivot, William Jacot, Hervé L. Naman, Dominique Spaeth, Jean-Louis Misset, Rémy Largillier, Jean-Loup Sautiere, Anne de Roquancourt, Christophe Pomel, Philippe Rouanet, Roman Rouzier, Frederique M. Penault-Llorca, for The Francilian Breast Intergroup

Because it is not possible to extrapolate data from one country to another, we considered generating specific data from French oncology centers to be highly relevant for making more accurate estimates of the health and economic impact of Oncotype DX use in the French health care system.
The Oncologist 2015; 20:873-879; first published on June 25, 2015; doi: 10.1634/theoncologist.2014-0467

Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium
Shanly C. Seferina, Dorien J.A. Lobbezoo, Maaike de Boer, M. Wouter Dercksen, Franchette van den Berkmortel, Roel J.W. van Kampen, Agnès J. van de Wouw, Bart de Vries, Manuela A. Joore, Petronella G.M. Peer, Adri C. Voogd, Vivianne C.G. Tjan-Heijnen

This study shows that in real life, patients treated with trastuzumab in early-stage HER2-positive breast cancer had a 5-year disease-free and overall survival comparable to prior randomized trials. For informative decision making, real-life data are of additional value, providing insight on outcome of patients considered ineligible for treatment.
The Oncologist 2015; 20:856-863; first published on June 22, 2015; doi:10.1634/theoncologist.2015-0006

Changing the Paradigm—Multistage Multiarm Randomized Trials and Stratified Cancer Medicine
Mark Lawler, Rick Kaplan, Richard H. Wilson, Tim Maughan, on behalf of the S-CORT Consortium

The increasing fragmentation of clinically recognized diseases into multiple separate biologically defined subtypes threatens the current cornerstone of evidence-based medicine—the randomized controlled trial.
The Oncologist 2015; 20:849-851; first published on June 12, 2015; doi:10.1634/theoncologist.2015-0014

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study
Matteo Lambertini, Arlindo R. Ferreira, Francesca Poggio, Fabio Puglisi, Antonio Bernardo, Filippo Montemurro, Elena Poletto, Emma Pozzi, Valentina Rossi, Emanuela Risi, Antonella Lai, Elisa Zanardi, Valentina Sini, Serena Ziliani, Gabriele Minuti, Silvia Mura, Donatella Grasso, Andrea Fontana, Lucia Del Mastro

In our study, we observed that trastuzumab-based therapy is an effective first-line therapy for patients exposed to (neo)adjuvant trastuzumab. However, trastuzumab-naïve patients showed a better PFS and a trend toward a better response rate to first-line trastuzumab-based therapy than did patients with previous exposure to (neo)adjuvant trastuzumab.
The Oncologist 2015; 20:880-889; first published on June 22, 2015; doi:10.1634/theoncologist.2015-0020

Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?
Marta Bonotto, Lorenzo Gerratana, Donatella Iacono, Alessandro Marco Minisini, Karim Rihawi, Gianpiero Fasola, Fabio Puglisi

This study supports evidence showing that the absence of a 6-month benefit in terms of progression-free survival with first-line therapy predicts a lack of benefit from subsequent therapeutic lines in metastatic breast cancer.
The Oncologist 2015; 20:719-724; first published on May 27, 2015; doi:10.1634/theoncologist.2015-0002

Reducing Cancer Mortality in the European Union
Carlo La Vecchia, Matteo Rota, Matteo Malvezzi and Eva Negri

Since the peak rate reached in 1988, overall age-standardized cancer mortality rates in the European Union have declined by approximately 20% through 2010. This study reviews different mortality analyses to allow comparisons among different years and countries with different age distributions.
First Published Online April 17, 2015; doi: 10.1634/theoncologist.2015-0011

Helical Tomotherapy in Head and Neck Cancer: A European Single-Center Experience
Dirk Van Gestel, Danielle Van den Weyngaert, Geert De Kerf, Bie De Ost, Olivier Vanderveken, Carl Van Laer, Pol Specenier, Yasmyne Geussens, Kristien Wouters, Els Meulemans, Kin Jip Cheung, Vincent Grégoire, Jan B. Vermorken

This article reports on a European single-center clinical experience with helical tomotherapy (HT) in the treatment of head and neck cancer to give a realistic reflection of the role of HT in daily practice for patient candidates for radiotherapy. HT alone or in combination with systemic therapy (ST) is feasible and promising, and it has a low late fatality rate. However, late toxicity is nearly twice as high when ST is added to HT.
The Oncologist 2015; 20:279-290; first published on February 11, 2015; doi:10.1634/theoncologist.2014-0337

The European Medicines Agency Review of Pomalidomide in Combination With Low-Dose Dexamethasone for the Treatment of Adult Patients With Multiple Myeloma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Zahra Hanaizi, Beatriz Flores, Robert Hemmings, Jorge Camarero, Arantxa Sancho-Lopez, Tomas Salmonson, Christian Gisselbrecht, Edward Laane, Francesco Pignatti

On August 5, 2013, a marketing authorization valid throughout the European Union was issued for pomalidomide in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy. This paper summarizes the scientific review of the application leading to that approval.
The Oncologist 2015; 20:329-334; first published on February 11, 2015; doi:10.1634/theoncologist.2014-0073

Brentuximab Vedotin in Patients With Hodgkin Lymphoma and a Failed Allogeneic Stem Cell Transplantation: Results From a Named Patient Program at Four Italian Centers
Carmelo Carlo-Stella, Francesca Ricci, Serena Dalto, Rita Mazza, Michele Malagola, Francesca Patriarca, Simonetta Viviani, Domenico Russo, Laura Giordano, Luca Castagna, Paolo Corradini, Armando Santoro

The aim of this study was to retrospectively evaluate the efficacy and safety of brentuximab vedotin (BV) in a multicenter setting of classical Hodgkin lymphoma relapsing or progressing after allogeneic stem cell transplant. Results showed that BV therapy is an effective and safe approach for achieving transient disease control in these patients. To improve disease control, future studies should explore the combination of BV with targeted agents.
The Oncologist 2015; 20:323-328; first published on February 10, 2015; doi:10.1634/theoncologist.2014-0420

External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Anti-EGFR Therapy in Colorectal Cancer
Véronique Tack, Marjolijn J.L. Ligtenberg, Lien Tembuyser, Nicola Normanno, Sara Vander Borght, J. Han van Krieken, Elisabeth M.C. Dequeker

Regulations for the selection of patients with metastatic colorectal cancer for anti-EGFR treatment changed at the end of 2013. A European external quality assessment scheme monitored the performance of laboratories and evaluated the implementation of the new regulations. The findings show great variety in the quality of cancer biomarker testing and should raise awareness about the importance of selecting reliable laboratories for biomarker testing in the context of targeted therapy decisions.
The Oncologist 2015; 20:257-262; first published on February 5, 2015; doi:10.1634/theoncologist.2014-0382

The European Medicines Agency Approval of Axitinib (Inlyta) for the Treatment of Advanced Renal Cell Carcinoma After Failure of Prior Treatment With Sunitinib or a Cytokine: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Kyriaki Tzogani, Venke Skibeli, Ingunn Westgaard, Marianne Dalhus, Hege Thoresen, Karsten Bruins Slot, Per Damkier, Kenneth Hofland, Jeanett Borregaard, Jens Ersbøll, Tomas Salmonson, Ronny Pieters, Richard Sylvester, Gerald Mickisch, Jonas Bergh, Francesco Pignatti

Based on a positive opinion from the European Medicines Agency, a marketing authorization valid throughout the European Union (EU) was issued for axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine. This paper summarizes the scientific review of the application leading to approval in the EU.
The Oncologist 2015; 20:196-201; first published on January 23, 2015; doi:10.1634/theoncologist.2014-0177

Public Perception of Cancer Care in Poland and Austria
Mariusz Jȩdrzejewski, Christiane Thallinger, Magda Mrozik, Gabriela Kornek, Christoph Zielinski, Jacek Jassem

A one-time survey was conducted to compare the public perception of cancer treatment in Poland and Austria. In total, 3,649 subjects, representing the general population, cancer patients, and cancer patients' family members, were surveyed. Vast differences in the perceptions of the two populations of cancer care reflect actual cancer outcomes and the national per capita spending on health-related issues.
The Oncologist 2015; 20:28-36; first published on December 17, 2014; doi:10.1634/theoncologist.2014-0226

International Collaboration and the Importance of Eubiosia
Stephan Tanneberger

The call of the oncologist is to improve quality of life, and to do so, oncologists can look beyond technology and expensive medications; these may not be necessary for patients to achieve eubiosia: no more pain and dignity of life until the last moment of life. Simple gestures of companionship, family, and care can make a difference.
The Oncologist 2015; 20:86-87; first published on December 9, 2014; doi:10.1634/theoncologist.2014-0427

Chemotherapy Dose Adjustment for Obese Patients Undergoing Hematopoietic Stem Cell Transplantation: A Survey on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Noga Shem-Tov, Myriam Labopin, Leila Moukhtari, Fabio Ciceri, Jordi Esteve, Sebastian Giebel, Norbert-Claude Gorin, Christopher Schmid, Avichai Shimoni, Arnon Nagler, Mohamad Mohty

An electronic survey was used to assess current practice of dose adjustment of chemotherapy in obese and overweight patients undergoing hematopoietic stem cell transplantation. It revealed large diversity among transplant centers regarding dose-adjustment practice. This novel survey is an important step toward defining the right dose adjustment for pretransplantation conditioning to improve efficacy, to reduce toxicity, and thus to improve transplantation outcome.
The Oncologist 2015; 20:50-55; first published on December 5, 2014; doi:10.1634/theoncologist.2014-0187

What Keeps Oncologists From Addressing Palliative Care Early on With Incurable Cancer Patients? An Active Stance Seems Key
Timo A. Pfeil, Katsiaryna Laryionava, Stella Reiter-Theil, Wolfgang Hiddemann, Eva C. Winkler

This qualitative study, based on a survey of care providers in a hospital in Munich, Germany, explores the factors that hinder sympathetic and frank communication about the terminal nature of advanced cancer and reconstructs how physicians and nurses in oncology perceive their roles in preparing patients for end-of-life decisions. The findings suggest that oncologists recognized a risk of nourishing patients' overly optimistic views in not talking openly and that it would be better to prepare patients proactively for decisions toward the end of life.
The Oncologist 2015; 20:56-61; first published on October 31, 2014; doi:10.1634/theoncologist.2014-0031

Return to Europian Highlights